Ruslan Novosiadly | Oncology Translational Medicine Team Lead
Bristol Myers Squibb

Ruslan Novosiadly, Oncology Translational Medicine Team Lead, Bristol Myers Squibb

Ruslan Novosiadly, MD, PhD (currently Translational Medicine Team Lead at Bristol-Myers Squibb (Princeton, NJ) is a translational scientist with 10+ years of academic/industrial experience and strong background in medical sciences, molecular/cell biology and translational oncology. He received MD degree from Ivano-Frankivsk State Medical Academy (Ivano-Frankivsk, Ukraine) followed by PhD degree in Biology from Georg-August University of Goettingen (Goettingen, Germany) and postdoctoral training at the Department of Medicine at Mount Sinai School of Medicine (New York, NY).
Dr Novosiadly joined ImClone Systems, a wholly owned subsidiary of Eli Lilly, in 2009. Over ~9 years at Eli Lilly, he contributed to translational and biomarker efforts in support of Cixutumumab (IGF-IR Antibody), Necitumumab, Ramucirumab, Abemaciclib and Pemetrexed, by providing insights into mechanisms of action and resistance and their ability to combine with other agents, particularly immune checkpoint inhibitors. Dr Novosiadly also built a technically diverse group utilizing high-content biomarker platforms to guide development of rational combinations in Immuno-Oncology, and represented Eli Lilly at external forums in support of marketed products.
In 2018 Dr Novosiadly joined Bristol-Myers Squibb where he represents Translational Medicine (TM) organization on the Early Asset Development Team, and is accountable for managing input from all TM functions (including Biomarkers, Bioinformatics, Translational Research & Technologies, Pharmacodiagnostics, Program & Sample Management) in establishing and driving the translational strategy across a number of programs spanning T cell agonists, innate immune agonists, cytokine therapy and oncolytic virotherapy.


Day 2, April 8 @ 09:40

Panel: Targeted approaches to combinations, what’s working?

  • What strategies can we use to identify the best combinations?
    • Using immunology as a guide?
    • Combinations of any active compound?
  • What are the major mechanisms we need to focus on?
  • How successful have targeted combinations been so far?
    • IO-IO/ IO-Non-IO combos / Targeting the TME / Angiogenesis inhibitors / Standard of care agents
  • What are the best biomarkers for combination studies?
  • What major challenges remain?
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates